Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model

BMC Research Notes

Table 1 Chou and Talalay combination indices for each cell line examined

	Gefitinib + ZSTK474	Erlotinib + ZSTK474	Gefitinib + Rapamycin	Erlotinib + Rapamycin	Gefitinib + ZSTK474	Erlotinib + ZSTK474	Gefitinib + Rapamycin	Erlotinib + Rapamycin
Cell Line	C150				C190
MCF10a Wt	0.23	0.58	0.02	0.28	0.47	0.42	0.03	0.07
MCF10a PI3K (H1047R)	1.15	0.93	1.09	0.89	0.18	0.39	0.46	0.40
MCF10a PI3K (E545K)	1.15	1.41	1.52	1.30	0.41	0.75	0.32	0.44
MCF10a EGFR (Δ E746-A750)	0.40	0.93	0.60	1.10	0.30	0.27	0.04	0.09
MCF10a BRAF (V 600E)	0.93	1.18	0.59	1.07	0.35	0.19	1.04	1.33
MCF10a Akt (E17K)	0.37	0.51	0.20	0.33	0.18	0.18	0.05	0.08

The combination index CI calculates synergism <0.8; additivity >0.8 and <1.2; antagonism >1.2. Synergism is noted in the wild type cell line, and in the Akt mutated line while there is some indication of antagonism in one PI3K mutated line.

ISSN: 1756-0500